TrippBio is developing a patent-pending repurposed FDA-approved drug, TD213. TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection. TrippBio is founded on the research of Ralph Tripp, Ph.D. the Georgia Research Alliance Chair and Professor at the University of Georgia.

Dr. Moti N. Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study (IIS) to assess the efficacy of TD213 in treating patients with confirmed mild - moderate COVD-19 infections. Dr. Ramgopal announced the final patient was enrolled in this proof of concept (POC) study and all participants are progressing through the protocol designated testing and follow-up visits. Recognized as one of the leading infectious disease doctors in the United States, Dr. Ramgopal's research center is committed to all the health needs of the patient.

"I am very encouraged by the initial patient response to the treatment with TD213. So far, the drug is well tolerated, and we are looking forward to analyzing the data on TD213 impact on viral clearance and markers of inflammation," When discussing the study, Dr. Ramgopal said.

"We are very impressed with the staff that managed the rapid enrollment of this study at the Midway Center. We plan to take the data from this study and the University of Georgia to the FDA in support of the rapid development of a pivotal Ph II/III study using TD213 in patients infected with COVID-19 and if applicable apply for an Emergency Use Authorization," Philip Young, CEO of TrippBio, said.